Aclaris Therapeutics, Inc. · NASDAQ:ACRS
Aclaris Therapeutics — 41st Annual J.P. Morgan Healthcare Conference (January 2023)
27 slides from Aclaris Therapeutics's conference presentation, Jan 9, 2023
Slide 1: Empowering Patients Through Kinome Innovation
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 41 st Annual J.P. Morgan Healthcare Conference January 2023 EMPOWERING PATIENTS THROUGH KINOME INNOVATION
Slide 2: Cautionary Note Regarding Forward-Looking Statements
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Cautionary Note Regarding Forward - Looking Statements 2 Any statements contained in this presentation that do not describe historical facts may
Slide 3: Biotechnology Company Focused on the Kinome
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Biotechnology Company Focused on the Kinome People + Platform + Pipeline 3 Note: KINect ® is the registered trademark of Aclaris Therapeutics, I
Slide 4: The Kinase Opportunity: Unlocking the Potential of the Kinome
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) The Kinase Opportunity Unlocking the Potential of the Kinome 4 Note: All trademarks are the property of their respective owners. 1. GoodRx. Acce
Slide 5: Precision Immunology with the KINect Platform
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Precision Immunology with the KINect Platform Demonstrated Success in Reversible and Covalent MOA 5 MK2 Inhibitors Unique kinase complex inhibit
Slide 6: Drug Development Pipeline
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Drug Development Pipeline 6 Drug Candidate / Program Target Route of Administration Indication Development Phase Topline Data Expected Immuno -
Slide 7: Zunsemetinib (ATI-450): MK2 Inhibitor
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 7 Zunsemetinib (ATI - 450): MK2 Inhibitor (Investigational Drug Candidate)
Slide 8: Evolution in Understanding of a Well-Known Path
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Evolution in Understanding of a Well - Known Path 8 Note: Wang C, et al. J Exp Med. 2018;215(5):1315 - 1325; Cheung P, et al. EMBO J. 2003;22(21
Slide 9: Novel Mechanism: Locking MK2 in an Inactive State
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Novel Mechanism: Locking MK2 in an Inactive State 9 Note: Wang C, et al. J Exp Med. 2018;215(5):1315 - 1325. • In the nucleus, inactive MK2 and
Slide 10: Zunsemetinib: Investigational Small Molecule, Oral MK2 Inhibitor
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0770 8/22) Zunsemetinib: Investigational Small Molecule, Oral MK2 Inhibitor Designed to Block the Targets of Broadly - Used Biologics 10 1. Data on file; 2
Slide 11: Zunsemetinib Demonstrated Strong Inhibition Across Key Cytokines
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Zunsemetinib Demonstrated Strong Inhibition Across Key Cytokines 11 Note: Data on file Zunsemetinib dosed orally BID for 7 days in healthy subje
Slide 12: Zunsemetinib Phase 2a Trial in Rheumatoid Arthritis
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Zunsemetinib Phase 2a Trial in Rheumatoid Arthritis Summary of Clinical Data 12 Summary of Efficacy Endpoints Potent and Durable Clinical Effica
Slide 13: On-Going Phase Studies: Zunsemetinib
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) On - Going Phase 2 Studies: Zunsemetinib 13 Hidradenitis Suppurativa 12 - week phase 2a randomized trial Psoriatic Arthritis 12 - week phase 2a
Slide 14: ATI-1777 (Topical Soft JAK Inhibitor)
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 14 ATI - 1777 (Topical “Soft” JAK Inhibitor) (Investigational Drug Candidate)
Slide 15: Aiming to Develop an Effective and Safe Therapy for Atopic Dermatitis
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Aiming to Develop an Effective and Safe Therapy for Atopic Dermatitis 15 1. Medscape. Accessed January 7, 2023. https://emedicine.medscape.com/a
Slide 16: Positive Data Demonstrated in ATI-1777 Phase 2 Study in Atopic Dermatitis
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Positive Data Demonstrated in ATI - 1777 Phase 2 Study in Atopic Dermatitis 16 0 20 40 60 80 100 mEASI50 mEASI75 mEASI90 ATI-1777 Vehicle Primar
Slide 17: Low Plasma Levels of ATI-1777 Following Topical Application
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Low Plasma Levels of ATI - 1777 Following Topical Application 17 Note: Data on file • All concentrations < ½ IC 50 (IC 50 = 36 ng/mL for JAK1/3)
Slide 18: ATI-1777 Status: Positive Proof of Concept
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) ATI - 1777 Status 18 Positive Proof of Concept First in Human Study • Moderate to Severe Atopic Dermatitis ✓ Traditionally the domain of systemi
Slide 19: ATI-2138 (ITK/JAK3 Inhibitor)
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 19 ATI - 2138 (ITK/JAK3 Inhibitor) (Investigational Drug Candidate)
Slide 20: ATI-2138: Covalent ITK/JAK3 Inhibitor
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) ATI - 2138: Covalent ITK/JAK3 Inhibitor with Potential for Ulcerative Colitis and other T Cell - Mediated Diseases 20 1. Data on file; 2. Graham
Slide 21: Simultaneous Stimulation of ITK and JAK3 Pathways Dose-Dependently Inhibited by ATI-2138
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Simultaneous Stimulation of the ITK and JAK3 Pathways was Dose - Dependently Inhibited by ATI - 2138 21 Assesses modulation of both ITK and JAK3
Slide 22: Wide Array of Disease Targets for ATI-2138
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) cGvHD Genital Psoriasis Acute Inflammatory Psoriasis Acute Severe Ulcerative Colitis Asthma SLE RA Crohn’s Disease Transplant Ulcerative Colitis
Slide 23: Corporate Highlights
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 23 Corporate Highlights
Slide 24: Empowering Patients Through Kinome Innovation
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Empowering Patients Through Kinome Innovation 24 Proven track record of R&D, business development and scientific leadership in immuno - inflamma
Slide 25: Experienced Leadership Team
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Experienced Leadership Team 25 Douglas Manion Chief Executive Officer Joseph Monahan Chief Scientific Officer James Loerop Chief Business Office
Slide 26: Drug Development Pipeline
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Drug Development Pipeline 26 Drug Candidate / Program Target Route of Administration Indication Partner Development Phase Immuno - Inflammatory
Slide 27: 2023 Expected Data Readouts
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 2023 Expected Data Readouts 27 Q4 2022 Mid 2023 H2 2023 Mid H1 2023 H2 2023 Initiated ATI - 2138 Multiple Ascending Dose Phase 1 ATI - 1777 AD P
Aclaris Therapeutics — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix